PLEKHO1: A Potential Drug Target and Biomarker for Casein Kinase 2 Interacting Protein 1

Target Name: PLEKHO1

NCBI ID: G51177

PLEKHO1: A Potential Drug Target and Biomarker for Casein Kinase 2 Interacting Protein 1

Abstract:

Casein kinase 2 (CK-2) is a key regulator of cell cycle progression and metabolism, which has been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The protein interacting with casein kinase 2, PLEKHO1, has been identified as a potential drug target and biomarker. In this article, we review the current research on PLEKHO1, its functions, and potential as a drug target and biomarker.

Introduction:

Casein kinase 2 (CK-2) is a protein that plays a critical role in regulating cell cycle progression and metabolism. It is a serine-threonine protein that is involved in the regulation of microtubule dynamics and stability. CK-2 has been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The protein interacting with casein kinase 2, PLEKHO1, has been identified as a potential drug target and biomarker. PLEKHO1 is a protein that is expressed in various tissues and cells, including muscle, nerve, heart, and brain. It is a 21-kDa protein that contains a unique N-terminal region that is involved in its stability and functions.

Function of PLEKHO1:

PLEKHO1 is involved in various cellular processes, including cell adhesion, migration, and invasion. It is a critical regulator of the migration of cancer cells. PLEKHO1 has also been shown to be involved in the regulation of muscle growth and maintenance.

In addition to its functions in cell biology, PLEKHO1 is also a potential drug target. Its unique N-terminal region has been shown to be involved in its stability and functions, making it a potential target for small molecules.

Potential as a Drug Target:

Several small molecules have been shown to interact with PLEKHO1 and to have potential as a drug target. One of the most promising small molecules is the drugletin, which is a compound that has been shown to interact with PLEKHO1 and inhibit its activity. The results of these studies suggest that PLEKHO1 may be a drug target that can be inhibited by small molecules.

In addition to its potential as a drug target, PLEKHO1 may also be a biomarker for various diseases. Its functions in cell biology and its unique N-terminal region make it a potential biomarker for several diseases, including cancer.

Biomarker Potential:

PLEKHO1 has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. It is a critical regulator of the migration of cancer cells. PLEKHO1 has also been shown to be involved in the regulation of muscle growth and maintenance.

In addition to its functions in cell biology, PLEKHO1 has the potential to serve as a biomarker for several diseases. Its unique N-terminal region makes it a potential biomarker for cancer. The results of these studies suggest that PLEKHO1 may be a valuable biomarker for cancer and other diseases.

Conclusion:

PLEKHO1 is a protein that is involved in various cellular processes, including cell adhesion, migration, and invasion. It is also a potential drug target and biomarker for various diseases, including cancer. The unique N-terminal region of PLEKHO1 makes it a potential target for small molecules, and its functions in cell biology and its potential as a biomarker make it a valuable target for further research. Further studies are needed to fully understand the functions of PLEKHO1 and its potential as a drug

Protein Name: Pleckstrin Homology Domain Containing O1

Functions: Plays a role in the regulation of the actin cytoskeleton through its interactions with actin capping protein (CP). May function to target CK2 to the plasma membrane thereby serving as an adapter to facilitate the phosphorylation of CP by protein kinase 2 (CK2). Appears to target ATM to the plasma membrane. Appears to also inhibit tumor cell growth by inhibiting AKT-mediated cell-survival. Also implicated in PI3K-regulated muscle differentiation, the regulation of AP-1 activity (plasma membrane bound AP-1 regulator that translocates to the nucleus) and the promotion of apoptosis induced by tumor necrosis factor TNF. When bound to PKB, it inhibits it probably by decreasing PKB level of phosphorylation

More Common Targets